Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China
· Delayed Price · Currency is CNY 93.57
+1.50 (1.63%)
Apr 29, 2026, 3:00 PM CST
Shanghai Allist Pharmaceuticals Company Description
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally.
The company’s lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).
It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC.
The company was founded in 2004 and is based in Shanghai, China.
Shanghai Allist Pharmaceuticals Co., Ltd.
| Country | China |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,989 |
| CEO | Jinhao Du |
Contact Details
Address: No. 268 Lingxiaohua Road Shanghai, 201318 China | |
| Phone | 86 21 8042 3292 |
| Website | allist.com.cn |
Stock Details
| Ticker Symbol | 688578 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005XJ7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jinhao Du | Chairman of the Board and GM |
| Jie Hu | Vice Chairman and Deputy GM |
| Lin Wang | Financial Director |
| Chen Huang | Marketing Manager |
| Feng Xu | Deputy GM and Director |
| Huafeng Shan | Chief Quality Officer |
| Huibing Luo | Chief Chemistry Officer |
| Shuo Li | Board Secretary |
| Quan Gan | Accounting Supervisor |
| Huayong Zhou | Deputy Director of Research & Development |